Regencell Bioscience's ADHD and ASD Treatment Second Efficacy Trial Progressing Smoothly

[Asia Economy Reporter Park Jihwan] Biotech company Regencell Bioscience Holdings Limited announced on the 8th that it is smoothly conducting the second efficacy trial for ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) treatments.

Regencell is a Nasdaq-listed biotech company based in Hong Kong, established in 2014. It is currently developing drugs based on Traditional Chinese Medicine (TCM) formulas derived from the Compendium of Materia Medica for the treatment of ADHD and ASD. After successfully completing the first efficacy trial, the company has been conducting the second efficacy trial since July last year.

In the first human efficacy trial, the TCM formula-based drug showed symptom improvement within three months of treatment initiation in all participating patients. Globally recognized comprehensive evaluation scores from four assessments?Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS), and Swanson, Nolan, and Pelham's 26-item Parent Rating Scale (SNAP-IV-26)?decreased on average by 40%, 32%, 32%, and 29%, respectively.

Since July last year, during the ongoing second efficacy trial, Regencell has been recruiting patients aged 5 to 13 in Hong Kong diagnosed with ADHD or ASD by medical professionals to continue evaluating the effects of the TCM formula-based drug on ADHD and ASD. Compared to the first study, evaluations on the 'quality of life' category have been added, collecting feedback from parents and guardians regarding improvements in caregiving and pre- and post-treatment life quality for ADHD and ASD patients.

Currently available ADHD and ASD treatments temporarily alleviate symptoms but do not address the root causes of the disorders. They often come with complex side effects such as sleep disturbances, loss of appetite, headaches, and stomachaches. In contrast, Traditional Chinese Medicine (TCM) is known for fewer side effects and pharmacological effects mainly including immune enhancement, memory improvement, gastrointestinal improvement, and neurocalming.

Yat-Gai Au, founder and CEO of Regencell, explained, "ADHD and ASD are known to be associated with increased medical expenses, special education costs, and parental job loss costs," adding, "By improving patients' conditions and reducing symptoms, we can lessen the impact of these disabilities on the children themselves and those around them."

This content was produced with the assistance of AI translation services.